Antoine Gaber

Professional Scientific Career

Antoine Gaber, known in the scientific community under Antoine Abugaber, has currently a Membership with the prestigious internationally renowned American Society of Clinical Oncology (ASCO), Gaber has been involved in the last 25 years in cancer research and drug development working mostly within multinational Pharmaceutical Companies. Gaber, former Associate Member, Interdepartmental Division of Oncology, Faculty of Medicine, University of Toronto, and former Member of the Medical Research & Development Section of the Canada's Research-Based Pharmaceutical Companies (Rx & D), supported one of his great passions: drug development.

In the late 1970's, at the beginning of Gaber's career, he had University teaching assignments at undergraduate (BSc.), graduate (MSc. PhD.) level in molecular biology, electron microscopy, and research in oncology at the University of Montreal.

During his career, Gaber held several important strategic positions in the Medical Department of several Multinational Pharmaceutical companies such as: Director of Clinical Operations, International Clinical Research and Development, and Medical Research Scientist, in Clinical Research Oncology.

During that period, Gaber contributed to the co-development of clinical programme, designed drug development programs, produced clinical trial plans, and wrote clinical trial reports mostly for oncology products, which resulted in numerous drug registrations to the health authorities in several countries. Gaber also contributed to new product entries in Canada and other countries by generating clinical trial data (Phase I to IIIb) resulting in the introduction of several new cancer drugs and indications in breast cancer, colorectal cancer, prostate cancer, multiple myeloma, and lung cancer.

In his scientific career, Gaber directed the activities of over 125 Canadian and international multi-centre (Phase I-IIIb) clinical trials and pre-clinical projects in tandem with the USA and the European Medical community. The studies were mostly in the area of oncology (breast, colorectal, prostate, multiple myeloma, lung, and ovarian cancer), bone metabolism and in a lesser extent in rheumatology, cardiology, infectious disease, gynaecology, central nervous system, dermatology and trauma, with an estimated budget of 21.3 million $ Can. with the total participation of over 475 clinical research sites within Canada. Gaber has also written and co-authored several articles and Abstracts published in Medical/Scientific Journals.

In 2002, Gaber was appointed to the prestigious position of Director of the Prescription Drug Program and Medicare at the Department Health & Wellness, at the Government in the Province of New Brunswick (NB). Gaber was responsible to brief the Premier of the Province of NB, and Minister of Health, on all issues relating to Prescription Drug Program (PDP) / Medicare and provide direction or guidance. Gaber was also responsible to ensure that entitled health services provided by all physicians, pharmacists and out of Province hospitals are accessible to the population, and managed over 29% of the total expenditures / operating cost of the Department of Health and Wellness for the Province of NB ($1.3 billion Can), with staff team of 83 people.

Gaber also President of Abugaber Canada, Oncology Management Services , specializing firm in the development, commercialization and licensing acquisition opportunities of oncology drugs, supporting the Pharmaceutical and Biotechnology corporation with a fully integrated service in oncology.